Navigation Links
Pharmasset to Present at the 28th Annual JPMorgan Healthcare Conference
Date:1/8/2010

l drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis C virus (HCV) and, secondarily, on the development of Racivir(TM) for the treatment of human immunodeficiency virus (HIV). Our research and development efforts focus on nucleoside/tide analogs, a class of compounds which act as alternative substrates for the viral polymerase, thus inhibiting viral replication. We currently have three clinical-stage product candidates. RG7128, a nucleoside analog for chronic HCV infection, is in a Phase 2b clinical trial in combination with Pegasys® plus Copegus® and is also in the phase 1b INFORM studies, the first series of studies designed to assess the potential of combinations of small molecules without Pegasys® and Copegus® to treat chronic HCV. These clinical studies are being conducted through a strategic collaboration with Roche. Our other clinical stage candidates include PSI-7851, an unpartnered, next generation HCV nucleotide analog, that has completed initial Phase 1 clinical studies which provided supportive safety and efficacy data to initiate a Phase 2a trial in 1Q 2010 and Racivir, for the treatment of HIV, which has completed a Phase 2 clinical trial. We have also recently announced the nomination of two purine nucleotide analogs, PSI-938 and PSI-879, for preclinical development.

Pegasys® and Copegus® are registered trademarks of Roche.


    Contact
    Richard E. T. Smith, Ph.D.
    VP, Investor Relations and Corporate Communications
    richard.smith@pharmasset.com
    Office: +1 (609) 613-4181

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of

1995: Statements in this press release regarding our business that are not historical facts are

"forward-looking stateme
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pharmasset Reports Fiscal Year End 2009 Financial Results
2. Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C
3. Pharmasset to Present at Lazard Capital Markets Healthcare Conference
4. Pharmasset Reports Positive Preliminary Antiviral Data With PSI-7851 for the Treatment of Hepatitis C
5. Pharmasset to Present at Goldman Sachs and Needham Healthcare Conferences
6. Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C
7. Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients
8. Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)
9. Pharmasset Reports Fiscal Year End 2008 Financial Results
10. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
11. Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... , July 28, 2014 CTI BioPharma ... it will report its second quarter 2014 financial results ... the U.S. financial markets. Following the announcement, members of ... to discuss the results and provide a general corporate ... to the event can be obtained as follows: ...
(Date:7/25/2014)... 2014 /PRNewswire-iReach/ -- "Australia Capsule Endoscopy Systems Market Outlook ... Capsule Endoscopy Systems market. The report provides value, in ... prices (in US dollars) within market segments: ... Capsule Endoscopes , Capsule Endoscopy Data Recorders ... also provides company shares and distribution shares data for ...
(Date:7/25/2014)... 25, 2014  CVS Caremark Corporation (NYSE: ... Tuesday, August 5, 2014, at 8:30 a.m. (EDT) with ... financial results. An audio webcast of the ... Relations portion of the CVS Caremark website for all ... . This webcast will be archived and available on ...
Breaking Medicine Technology:CTI BioPharma to Report Second Quarter 2014 Financial Results on August 4, 2014 2Australia Capsule Endoscopy Systems Market Analysis and Forecast to 2020 2Australia Capsule Endoscopy Systems Market Analysis and Forecast to 2020 3Australia Capsule Endoscopy Systems Market Analysis and Forecast to 2020 4Australia Capsule Endoscopy Systems Market Analysis and Forecast to 2020 5
... 07, 2007 /PRNewswire-FirstCall/ --,Mymetics Corporation announced today ... vaccine elicited neutralizing,IgA mucosal antibodies in a ... as a possible first line of defense,against ... by Sylvain,Fleury, Ph.D., Mymetics' Chief Scientific Officer, ...
... 7, 2007 - Dynogen,Pharmaceuticals, Inc. reported positive ... trial of DDP733 for,gastroesophageal reflux disease (GERD). ... DDP733 as a treatment for,nocturnal GERD (NGERD). ... significance over placebo on the primary endpoint ...
Cached Medicine Technology:Mymetics' HIV Vaccine Demonstrates First-Ever Production of,Neutralizing IgA Antibodies in Non-Human Primate Model 2Mymetics' HIV Vaccine Demonstrates First-Ever Production of,Neutralizing IgA Antibodies in Non-Human Primate Model 3Mymetics' HIV Vaccine Demonstrates First-Ever Production of,Neutralizing IgA Antibodies in Non-Human Primate Model 4Dynogen Reports Positive Results in Phase 1B GERD Study 2Dynogen Reports Positive Results in Phase 1B GERD Study 3Dynogen Reports Positive Results in Phase 1B GERD Study 4
(Date:7/28/2014)... July 28, 2014 A St. Jude ... adult survivors of childhood cancer more than doubled their ... by failing to follow a heart-healthy lifestyle. The results ... , Almost 32 percent of the 1,598 adult survivors ... an umbrella term for health risk factors like high ...
(Date:7/28/2014)... July 2014: ESC Congress 2014 promises to be bigger, ... Keith Fox, Chair of the Congress Programme Committee. The ... most influential cardiovascular event every year in August. Record ... this year and the congress is on track to ... , Asked why an extra hot line session ...
(Date:7/28/2014)... group of researchers in Taiwan has developed a new ... early complication of diabetes sooner, when it is more ... in clinical trials, it may pave the way for ... complication, called diabetic autonomic neuropathy, which is common among ... The condition progressively affects the autonomic nerves controlling vital ...
(Date:7/28/2014)... Brea, CA (PRWEB) July 28, 2014 ... management business process outsourcing (BPO) for Fortune 500 brands, ... 2,500 jobs across its locations in Wisconsin, California, Florida ... will be based at its Brea campus. , A ... clients, which have seasonal ramp-ups that require additional staffing ...
(Date:7/28/2014)... Brisbane, Australia (PRWEB) July 28, 2014 ... achieve a happier lifestyle can often be a struggle ... international channel, psychic and medium, Lynette Leckie-Clark provides simple ... new book “The Magic of You.” With inspiring spiritual ... thinking, you can find empowerment, confidence and motivation for ...
Breaking Medicine News(10 mins):Health News:Unhealthy Habits More than Double Risk of Metabolic Syndrome in Childhood Cancer Survivors 2Health News:Unhealthy Habits More than Double Risk of Metabolic Syndrome in Childhood Cancer Survivors 3Health News:Unhealthy Habits More than Double Risk of Metabolic Syndrome in Childhood Cancer Survivors 4Health News:ESC Congress 2014 focuses on innovations in cardiology 2Health News:ESC Congress 2014 focuses on innovations in cardiology 3Health News:Wearable device for the early detection of common diabetes-related neurological condition 2Health News:Alta Resources to Fill Approximately 700 Positions in Brea 2Health News:Alta Resources to Fill Approximately 700 Positions in Brea 3Health News:Be Empowered to Achieve Happiness from New Book "The Magic of You" 2
... being fed contaminated feed is causing concern among the people. The ... years . The FDA is quick to play down the fear ... ,This concern came to light after some 38 chicken farms in ... farms fed the chicken for human consumption with the contaminated feed. ...
... C (HCV), survival has improved over time. However, for ... to a study in the issue of Liver Transplantation. ... reason for liver transplantation in the U.S., however, previous ... as well to liver transplantation. The difference has become ...
... governor, James E. McGreevy appears to be knocking on a ... the news for the right reasons. He has been ... ,Former Gov. James E. McGreevy, who was brought up as ... on Sunday at St. Bartholomew's Church in New York. He ...
... said the government is working to draft a law allowing ... of genetic disorders. ,"We are studying it from ... choice to have the abortion will be under the umbrella ... religious and social environment," Ali Shakar of the ministry of ...
... more than twice as likely to also have symptoms of ... not have migraines, according to research. ,The study involved ... screening questionnaire within 90 days after returning from one year ... the soldiers, or 60 percent, completed the questionnaire. Of those, ...
... warming, but only few act. ,The ... has two parts. One, human beings get stubbornly comfortable in ... programmed to act in its own best interests - and ... point. ,In addition, the overwhelming size and abstract ...
Cached Medicine News:Health News:Tainted Pet Food a Health Risk for Human? 2Health News:HCV Patients Survival After Liver Transplantation is Not Improving 2Health News:Migraines may Be a Symptom of Other Problems for Iraq Soldiers 2Health News:Why Humans Fail to Act on Climate Change 2Health News:Why Humans Fail to Act on Climate Change 3
... operating and recovery room, ,The Cardiocap ... haemodynamic and airway gas monitoring for induction ... units. The Cardiocap II is available in ... haemodynamic measurements. Two of the models include ...
Precordial Chestpieces are manufactured from chrome plated brass. Provides a hollow design with deep sound chambers for optimum acoustics....
For accurately monitoring heart and breath sounds....
For accurately monitoring core temperature and heart and breath sounds....
Medicine Products: